Clinical trials: Bladder Disease
Bladder Carcinoma
TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
This pilot clinical trial studies how well TracelT hydrogel works in localizing bladder tumors in patients undergoing radiation therapy for bladder cancer.
- Trial name
- NCT03125226
- Testing
- Polyethylene Glycol Hydrogel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship
This phase I trial investigates how well a healthy eating program works in improving outcomes in patients with bladder cancer. The behavioral dietary program consists of educational materials, live phone calls, and interactive…
- Conditions
- Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- NCT04548193
- Testing
- Behavioral Dietary Intervention, Educational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Overactive Bladder
Procedural Discomfort Related to Number of Intradetrusor Botox Injections
Injection of intradetrusor OnabotulinumtoxinA (BTX-A) is a highly efficacious therapy with a reliable safety profile and demonstrable improvements in subjective and objective measures for overactive bladder (OAB) symptom control.
- Trial name
- BIND (NCT05652036)
- Testing
- Intradetrusor Botox Injections
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- The Methodist Hospital Research Institute
Bladder Cancer
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
The purpose of this study is to evaluate whether adding pembrolizumab (Keytruda) to the combination of gemcitabine and cisplatin will improve shrinkage of the tumor before having a cystectomy, for people with muscle-invasive…
- Trial name
- NCT02690558
- Testing
- pembrolizumab, gemcitabine and cisplatin
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pressure Ulcers Stage III, Pressure Ulcer, Stage IV
Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries
The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 \& 4 pressure ulcers using ACell products.
- Conditions
- Pressure Ulcers Stage III, Pressure Ulcer, Stage IV, Pressure Ulcer
- Trial name
- NCT03283787
- Testing
- MicroMatrix® and Cytal™ Wound Matrix 2-Layer, MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT, Negative Pressure Wound Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Integra LifeSciences Corporation
Interstitial Cystitis
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain…
- Trial name
- NCT00086684
- Testing
- Pentosan polysulfate sodium 100 mg
- Where
- 65 sites in United States, Canada
- Volunteers
- 369 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Vaginal Prolapse
Observational Data Collection of Surgical Outcomes in the Treatment of Vaginal Prolapse With AMS Products
This registry was observational (only collected information typically noted by the surgeon when their patients were routinely seen); there was no change to the care the patient received as a result of being part of the registry).
- Trial name
- POWER1012 (NCT00388947)
- Testing
- AMS Prolapse Product
- Where
- United States
- Volunteers
- 1,543 people
- Sponsor
- ASTORA Women's Health
Urge Incontinence, Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants.
- Trial name
- NCT04562090
- Testing
- mirabegron
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma China, Inc.
Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)
The purpose of this study is to see what the effect of Botox has on bladder function for those who have recently suffered spinal cord injury.
- Trial name
- NCT00711087
- Testing
- BOTOX-A, Saline injection
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Baylor College of Medicine
Lymphoma, Digestive System Diseases
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Incidence of cancer in 75+ years old is 16,500 new cases per year, more than fifty percent of people with cancerThey are very few therapeutic trials dedicated.
- Conditions
- Lymphoma, Digestive System Diseases, Ovarian Diseases, Pulmonary Disease
- Trial name
- PHRC2003 (NCT00210249)
- Where
- 18 sites in France
- Volunteers
- 364 people
- Sponsor
- Institut Bergonié
Overactive Bladder
Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder
The specific aim of this trial is to determine if hydrodistention at the time of intradetrusor injection of botulinum toxin A has additional benefit in patients with refractory overactive bladder (OAB) and urgency symptoms…
- Trial name
- HydrA (NCT02995967)
- Testing
- Hydrodistention, Botulinum toxin-A
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Bladder Cancer
Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
The goal of this clinical research study is to learn how well bladder cancer responds to a combination treatment with Avastin and M-VAC (methotrexate, doxorubicin, vinblastine, and cisplatin) before surgery to remove the tumor.
- Trial name
- NCT00506155
- Testing
- Avastin, Cisplatin, Doxorubicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease
Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
This is a Phase 1/2(b), sequential, dose escalation, open-label, randomized expansion, multicenter, efficacy and safety study of vofatamab alone or in combination with docetaxel, or versus docetaxel in FGFR3 mutant/fusion…
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Trial name
- FIERCE-21 (NCT02401542)
- Testing
- Vofatamab, Docetaxel
- Where
- 65 sites in United States, Czechia and 7 more
- Volunteers
- 71 people
- Sponsor
- Rainier Therapeutics
Urinary Bladder, Overactive
Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy
Collect information on treatment with Toviaz (fesoterodine) under ordinary prescribing conditions, and to investigate whether additional educational information affects satisfaction with treatment as perceived by the patient.
- Trial name
- NCT01091519
- Testing
- Toviaz(fesoterodine) plus educational materials, Toviaz(fesoterodine) without educational materials
- Volunteers
- 781 people
- Sponsor
- Pfizer
Overactive Bladder
Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS)
Study objectives: To report feasibility data for safety and effectiveness of the study device. Study device: Nine Continents Medical implantable tibial nerve stimulator (ITNS) model 9C-680 with programmer model 9C-580.
- Trial name
- NCT04115228
- Testing
- Implantation and neuromodulation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Nine Continents Medical, Inc.
Bladder Cancer, Urothelial Carcinoma
A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
This Phase 2b, single-arm, multicenter study evaluated the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC).
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- OPTIMA II (NCT03558503)
- Testing
- UGN-102
- Where
- 19 sites in United States, Israel
- Volunteers
- 63 people
- Sponsor
- UroGen Pharma Ltd.
Overactive Bladder, Urinary Urge Incontinence
InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study
Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation.
- Conditions
- Overactive Bladder, Urinary Urge Incontinence, Urgency-frequency Syndrome
- Trial name
- BASIC (NCT04016324)
- Testing
- InterStim Basic Evaluation lead and foramen needle
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 110 people
- Sponsor
- MedtronicNeuro
Urinary Bladder Cancer, Muscle-invasive
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC).
- Trial name
- NCT03924895
- Testing
- Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
- Where
- 242 sites in United States, Argentina and 26 more
- Volunteers
- 595 people
- Sponsor
- Merck Sharp & Dohme LLC